|
1
|
Colozza M, Azambuja E, Cardoso F, Sotiriou
C, Larsimont D and Piccart MJ: Proliferative markers as prognostic
and predictive tools in early breast cancer: Where are we now? Ann
Oncol. 16:1723–1739. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mamede M, Higashi T, Kitaichi M, Ishizu K,
Ishimori T, Nakamoto Y, Yanagihara K, Li M, Tanaka F, Wada H, et
al: [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions
in cancers and inflammatory lesions of the lung. Neoplasia.
7:369–379. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shields AF, Grierson JR, Dohmen BM,
Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O
and Mangner TJ: Imaging proliferation in vivo with [F-18]FLT and
positron emission tomography. Nat Med. 4:1334–1336. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grierson JR and Shields AF: Radiosynthesis
of 3′-deoxy-3′-[18F]fluorothymidine: [18F]FLT for imaging of
cellular proliferation in vivo. Nucl Med Biol. 27:143–156. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rasey JS, Grierson JR, Wiens LW, Kolb PD
and Schwartz JL: Validation of FLT uptake as a measure of thymidine
kinase-1 activity in A549 carcinoma cells. J Nucl Med.
438:1210–1217. 2002.
|
|
6
|
Buck AK, Halter G, Schirrmeister H,
Kotzerke J, Wurziger I, Glatting G, Mattfeldt T, Neumaier B, Reske
SN and Hetzel M: Imaging proliferation in lung tumours with PET:
18F-FLT versus 18F-FDG. J Nucl Med. 44:1426–1431. 2003.PubMed/NCBI
|
|
7
|
Mier W, Haberkorn U and Eisenhut M:
[18F]FLT; portrait of a proliferation marker. Eur J Nucl Med Mol
Imaging. 29:165–169. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shields AF: Positron emission tomography
measurement of tumour metabolism and growth: Its expanding role in
oncology. Mol Imaging Biol. 8:141–150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
McKinley ET, Smith RA, Zhao P, Fu A, Saleh
SA, Uddin MI, Washington MK, Coffey RJ and Manning HC:
3′-Deoxy-3′-18F-fluorothymidine PET predicts response to
(V600E)BRAF-targeted therapy in preclinical models of colorectal
cancer. J Nucl Med. 54:424–430. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mason NS, Lopresti BJ, Ruszkiewicz J, Dong
X, Joyce S, Leef G, Sen M, Wahed AS, Mathis CA, Grandis JR and
Thomas SM: Utility of 3′-[(18)F]fluoro-3′-deoxythymidine as a PET
tracer to monitor response to gene therapy in a xenograft model of
head and neck carcinoma. Am J Nucl Med Mol Imaging. 3:16–31.
2013.PubMed/NCBI
|
|
11
|
Hoeben BA, Troost EG, Span PN, van Herpen
CM, Bussink J, Oyen WJ and Kaanders JH: 18F-FLT PET during
radiotherapy or chemoradiotherapy in head and neck squamous cell
carcinoma is an early predictor of outcome. J Nucl Med. 54:532–540.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang H, Liu B, Tian J, Xu B, Zhang J, Qu B
and Chen Y: Evaluation of 18F-FDG and 18F-FLT
for monitoring therapeutic responses of colorectal cancer cells to
radiotherapy. Eur J Radiol. 82:e484–e491. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li Z, Herrmann K, Pirsig S,
Philipp-Abbrederis K, Henninger M, Aichler M, Feuchtinger A, Walch
A, Beer AJ, Ringshausen I, et al: Molecular imaging for early
prediction of response to Sorafenib treatment in sarcoma. Am J Nucl
Med Mol Imaging. 4:70–79. 2013.PubMed/NCBI
|
|
14
|
Geven EJ, Evers S, Nayak TK, Bergström M,
Su F, Gerrits D, Franssen GM and Boerman OC: Therapy response
monitoring of the early effects of a new BRAF inhibitor on melanoma
xenograft in mice: Evaluation of (18) F-FDG-PET and (18) F-FLT-PET.
Contrast Media Mol Imaging. 10:203–210. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Keen HG, Ricketts SA, Maynard J, Logie A,
Odedra R, Shannon AM, Wedge SR and Guichard SM: Examining changes
in [18 F]FDG and [18 F]FLT uptake in U87-MG glioma xenografts as
early response biomarkers to treatment with the dual mTOR1/2
inhibitor AZD8055. Mol Imaging Biol. 16:421–430. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Krohn KA, Mankoff DA, Muzi M, Link JM and
Spence AM: Ture tracers: Compraring FDG with glucose and FLT with
thymidine. Nucl Med Biol. 32:663–671. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Grasl-Kraupp B, Ruttkay-Nedecky B,
Müllauer L, Taper H, Huber W, Bursch W and Schulte-Hermann R:
Inherent increase of apoptosis in liver tumors: implications for
carcinogenesis and tumor regression. Hepatology. 25:906–912. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kolaja KL, Stevenson DE, Walborg EF Jr and
Klaunig JE: Reversibility of promoter induced hepatic focal lesion
growth in mice. Carcinogenesis. 17:1403–1407. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Monteiro LJ, Khongkow P, Kongsema M,
Morris JR, Man C, Weekes D, Koo CY, Gomes AR, Pinto PH, Varghese V,
et al: The Forkhead Box M1 protein regulates BRIP1 expression and
DNA damage repair in epirubicin treatment. Oncogene. 32:4634–4645.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Been LB, Suurmeijer AJ, Cobben DC, Jager
PL, Hoekstra HJ and Elsinga PH: [18F]FLT-PET in oncology: Current
status and opportunities. Eur J Nucl Med Mol Imaging. 31:1659–1672.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Munch-Petersen B, Cloos L, Jensen HK and
Tyrsted G: Human thymidine kinase 1. Regulation in normal and
malignant cells. Adv Enzyme Regul. 35:69–89. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Boothman DA, Davis TW and Sahijdak WM:
Enhanced expression of thymidine kinase in human cells following
ionizing radiation. Int J Radiat Oncol Biol Phys. 30:391–398. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kauffman MG and Kelly TJ: Cell cycle
regulation of thymidine kinase: Residues near the carboxyl terminus
are essential for the specific degradation of the enzyme at
mitosis. Mol Cell Biol. 11:2538–2546. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cole PD, Smith AK and Kamen BA:
Osteosarcoma cells, resistant to methotrexate due to nucleoside and
nucleobase salvage, are sensitive to nucleoside analogs. Cancer
Chemother Pharmacol. 50:111–116. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Foekens JA, Romain S, Look MP, Martin PM
and Klijn JG: Thymidine kinase and thymidylate synthase in advanced
breast cancer: Response to tamoxifen and chemotherapy. Cancer Res.
61:1421–1425. 2001.PubMed/NCBI
|
|
26
|
Dittmann H, Dohmen BM, Kehlbach R,
Bartusek G, Pritzkow M, Sarbia M and Bares R: Early changes in
[18F]FLT uptake after chemotherapy: An experimental study. Eur J
Nucl Med Mol Imaging. 29:1462–1469. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dittmann H, Dohmen BM, Paulsen F, Eichhorn
K, Eschmann SM, Horger M, Wehrmann M, Machulla HJ and Bares R:
[18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J
Nucl Med Mol Imaging. 30:1407–1412. 2003. View Article : Google Scholar : PubMed/NCBI
|
